45th week of 2012 patent applcation highlights part 44 |
Patent application number | Title | Published |
20120283268 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers - Thiazole and thiophene compounds are disclosed having utility in treating inflammatory conditions, immunoinflammatory conditions, autoimmune diseases, and cancers. Methods for the synthesis of these compounds are also disclosed. | 2012-11-08 |
20120283269 | Method and Compositions for Suppression of Aging - The present invention provides a method of suppression and/or deceleration of mammalian cellular aging. The method involves contacting mammalian cells with a composition that contains a non-genotoxic inducer of p53 (NGIP). In certain embodiments, the NCIP is a Mdm-binding agent or Mdm-2 antagonist. The NGIP can be nutlin, nutlin-3A, a nutlin analog, or a combination thereof. The invention also provides a method for reducing cellular hypertrophy in an organism by administering a composition that contains an anti-hypertrophic compound, such as nutlin, nutlin-3A, a nutlin analog, rapamycin or a rapamycin analog and combinations thereof, to the organism. | 2012-11-08 |
20120283270 | EXTRACTS AND BEVERAGES CONTAINING 2,5-PIPERAZINEDIONE,3,6-BIS(PHENYLMETHYL)-, (3S,6S)- - The present invention aims to provide extracts or beverages containing 2,5-piperazinedione,3,6-bis(phenylmethyl)-,(3S,6S)—, which is a useful substance with an improving effect on learning motivation, in an easy-to-ingest form and at a high concentration. Extracts or beverages whose ratio between the content of 2,5-piperazinedione,3,6-bis(phenyl-methyl)-,(3S,6S)— (unit: μg/100 g) and Brix(Bx) is 6 (μg/100 g)/Bx or more can be ingested continuously over a long period of time as foods and beverages useful for improvement of learning motivation. | 2012-11-08 |
20120283271 | ISOINDOLINONE DERIVATIVES - The present invention relates to compounds of the formula I, | 2012-11-08 |
20120283272 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to certain compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. | 2012-11-08 |
20120283273 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR - This invention relates to modulation of the α7 nicotinic acetylcholine receptor (nAChR) by a compound of formula (I) or a pharmaceutically acceptable salt thereof. | 2012-11-08 |
20120283274 | CRYSTALLINE FORMS OF SUBSTITUTED PYRAZOLOPYRIMIDINES - The present invention relates to novel co-crystals of pyrazolopyrimidines and a co-crystal former, wherein the co-crystal former is an organic carboxylic acid, preferably selected from the group of gentisic acid, succinic acid and xinafoic acid. | 2012-11-08 |
20120283275 | METHODS AND DOSAGE FORMS FOR REDUCING SIDE EFFECTS OF BENZISOZAZOLE DERIVATIVES - Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivatives when dosed to a patient. | 2012-11-08 |
20120283276 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2012-11-08 |
20120283277 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2012-11-08 |
20120283278 | COMBINATION - The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof. | 2012-11-08 |
20120283279 | COMBINATION - A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a mTOR inhibitor, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or mTOR is beneficial, e.g. cancer. | 2012-11-08 |
20120283280 | IMIDAZOTETRAZINONE-BASED COMBI-MOLECULES - A series of new chemical agents that demonstrate anti-tumor activity are described herein. The new chemical agents exhibit a dual mode of anti-tumor action: blocking epidermal growth factor receptor (EGFR) mediated signal transduction and damaging DNA by alkylation. | 2012-11-08 |
20120283281 | NEW (POLY)AMINOALKYLAMINOALKYLAMIDE, ALKYL-UREA, OR ALKYL-SULFONAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN, A PROCESS FOR PREPARING THEM, AND APPLICATION THEREOF IN THERAPY AS ANTICANCER AGENTS - The present invention relates to new derivatives of epipodophyllotoxin 4-substituted with an optionally substituted (poly)aminoalkylaminoalkylamide, or alkyl-urea or alkyl-sulfonamide chain, a process for preparing them and their use as a medicine as an anticancer agent. | 2012-11-08 |
20120283282 | Photoproducts of Tryptophan, Their Synthesis and Uses Thereof - We have found that exposure of an aqueous tryptophan solution to window sunlight results in the production of multiple tryptophan photoproducts that have the capability of activating the aryl hydrocarbon receptor and increasing the production of AhR target genes and proteins in hepatocytes. We have isolated three of those photoproducts not previously identified as AhR activators, their chemical identification and synthesis and the demonstration that all three have biologic activities as novel AhR activators. Further, one of the three is a completely novel, not previously described, chemical compound. | 2012-11-08 |
20120283284 | MELONINE BISINDOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHOD AND USE THEREOF - The present invention relates to pharmaceutical technical field, to melonine bisindole compounds, pharmaceutical compositions thereof, and preparation methods thereof. Specifically, the present invention relates to melonine bisindole compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts thereof. The present invention further relates to method for preparing the melonine bisindole compounds of Formula I or pharmaceutically acceptable salts thereof, and the use of the melonine bisindole compounds of Formula I or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of cancers. | 2012-11-08 |
20120283285 | TREATMENT OF SOLID TUMORS WITH RAPAMYCIN DERIVATIVES - Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent. | 2012-11-08 |
20120283286 | METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY - Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”). | 2012-11-08 |
20120283287 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed. | 2012-11-08 |
20120283288 | 1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,- 3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (I) (for convenience, collectively referred to herein as “IP compounds”), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterised by (e.g., driven by) mutant RAS (“mutant RAS cancer”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer. | 2012-11-08 |
20120283289 | CRYSTALLINE FORM OF A BIPHENYL COMPOUND - The invention provides a crystalline 1,2-ethanedisulfonic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof. This invention also provides pharmaceutical compositions comprising such a salt or prepared using such a salt; processes and intermediates for preparing such a salt; and methods of using such a salt to treat a pulmonary disorder. | 2012-11-08 |
20120283290 | QUANTITATION OF GL3 IN URINE - The present invention is directed to the quantitation of GL3 in human urine which can be used for the diagnosis of Fabry disease as well as for the assessment of treatment efficacy thereof. | 2012-11-08 |
20120283291 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING DONEPEZIL HYDROCHLORIDE - The invention relates to a solid pharmaceutical composition comprising donepezil hydrochloride hydrate and a process for its preparation. In particular it relates to a composition and a process wherein the donepezil hydrochloride retains its polymorphic form and is therefore highly stable against conversion into other polymorphic forms. | 2012-11-08 |
20120283292 | FATTY ACID LENALIDOMIDE AND THEIR USES - The invention relates to fatty acid lenalidomide derivatives; compositions comprising an effective amount of a fatty acid lenalidomide derivative; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid lenalidomide derivative. | 2012-11-08 |
20120283293 | Methods of neuroprotection involving Prostaglandin E2 EP4 (PGE2 EP4) receptor activation - The present invention provides methods for attenuating neuronal inflammation and neuronal damage in case of acute or chronic injury of nerve cells of the central nervous system through prostaglandin E2 EP4 receptor activation. Methods for treating neuropathic pain are also provided. | 2012-11-08 |
20120283294 | CO-CRYSTAL OF 4-FURAN-2(5H)-ONE WITH BENZOIC ACID AND USE THEREOF AS PESTICIDE - The invention relates to a new co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino} furan-2(5H)-one with benzoic acid, to processes for the preparation thereof and use thereof. | 2012-11-08 |
20120283295 | INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS - The invention provides an indazole derivative of formula (1), or a pharmaceutically acceptable salt or N-oxide thereof, wherein R | 2012-11-08 |
20120283296 | PYRROLOPYRAZOLES FOR TREATING CNS DISORDERS - Provided herein are methods of utilizing PAK inhibitors for the treatment of CNS disorders. | 2012-11-08 |
20120283297 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS - Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed. | 2012-11-08 |
20120283298 | METHODS FOR TREATING MEMORY IMPAIRMENT - Methods for administering a therapeutically effective amount of a somatostatin receptor-4 (SSTR4) agonist in order to treat learning and memory impairment for Alzheimer's disease is disclosed. | 2012-11-08 |
20120283299 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient - A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc. | 2012-11-08 |
20120283300 | USE OF BENZO-HETEROCYCLE DERIVATIVES FOR PREVENTING AND TREATING CANCER OR FOR INHIBITING CANCER METASTASIS - This application relates to a novel benzo-heterocycle derivative and more particularly, it relates a composition for preventing and treating cancer or for inhibiting metastasis comprising benzo-heterocycle derivative or pharmaceutically acceptable salts thereof as an active ingredient. The present inventors confirmed that KRS has an effect on cancer metastasis by facilitating cancer (or tumor) cell migration through interaction with 67LR, and also found that a substance inhibiting the interaction between KRS and 67LR can prevent and treat cancer by inhibiting cancer cell metastasis. Accordingly, the composition of the present invention can inhibit cancer metastasis, and thus provide a novel means for prevention and treatment of cancer. | 2012-11-08 |
20120283301 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE - A series of S-triazolyl α-mercaptoacetanilides having general structure (1) are provided, where Q is CO | 2012-11-08 |
20120283302 | SCCA-1 PRODUCTION INHIBITOR HAVING A CARBOXAMIDE DERIVATIVE AND/OR A SALT THEREOF AS AN ACTIVE INGREDIENT - A SCCA-1 production inhibitor, comprising as an active ingredient, at least one carboxamide derivative selected from the group consisting of compounds represented by the following formula (I): | 2012-11-08 |
20120283303 | USE OF N-AMINOIMIDAZOLE CYTOPROTECTIVE COMPOUNDS FOR TREATING CELL DEATH AND/OR GSK-3 MEDIATED DISEASES - The present invention relates to the use of N-aminoimidazole or N-aminoimidazole thione derivatives as cytoprotective compounds in vitro and in vivo and for the treatment or prevention of cell death mediated disorders and/or GSK-3 mediated disorders or processes. | 2012-11-08 |
20120283304 | Formulations of Temozolomide for Parenteral Administration - The present invention relates to a parenteral formulation of Temozolomide comprising an excipient selected from the group consisting of bulking agents, buffers, pH adjusting agents, with the proviso that the formulation is free of dissolution enhancing agents. | 2012-11-08 |
20120283305 | CYSTEINE PROTEASE INHIBITORS - Compounds of the formula I | 2012-11-08 |
20120283306 | MOUSE MODEL FOR AVM - Arteriovenous malformation, or Arteriovenous vascular malformation (AVM) is a congenic disorder characterized by an abnormal connection between veins and arteries, resulting in hemorrhaging and even death. A lack of good animal models has long been an obstacle for identifying effective drugs for neurological AVM treatment. Describe herein is a mouse model for AVM that includes a viable, postnatal animal with a conditional deletion of the activin receptor-like kinase 1 (Alk1;Acvrl1). The Alk1-cKO mouse model can be used to identify genes and gene products that are upregulated in subjects suffering from AVM. For example, it has been discovered Agpt2, IL1β, and TNF-α, are upregulated in Alk1-cKO compared to controls. Pharmaceutical compositions for treatment of AVM are disclosed. Preferred compositions inhibit or decrease expression of angiogenic and pro-inflammatory factors, such as VEFG, Cox-2, Agpt2, IL1β, TNF-α, and matrix metalloproteinases. Methods of determining efficacy of potential AVM therapeutics are also disclosed. | 2012-11-08 |
20120283307 | USE OF AN INDAZOLEMETHOXYALKANOIC ACID FOR REDUCING TRIGLYCERIDE, CHOLESTEROL AND GLUCOSE LEVELS - A method of treating insulin resistance, obesity and metabolic syndrome by administering an indazolemethoxyalkanoic acid as described herein. | 2012-11-08 |
20120283308 | ANIMAL FEED COMPOSITION - Disclosed is an animal feed composition that comprises free indole acetic acid (free IAA) or a derivative thereof. Also disclosed is a method for enhancing animal growth by feeding the animal with a composition according to the invention. Further disclosed is the use of free IAA or a derivative thereof in a method of therapy of animals in need of a growth-promoting treatment, such as immunocompromised animals, animals with a growth deficit or slow-growing animals. Disclosed is the use of free IAA or a derivative thereof for the preparation of a therapeutical composition for increasing the growth rate and/or the feed conversion rate and/or the immunity of animals in need of such a treatment, in particular, immunocompromised or slow-growing animals. A composition may be in the form of a food or feed supplement. | 2012-11-08 |
20120283309 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS - The invention relates to modified siRNA compounds which down-regulate target gene expression, to pharmaceutical compositions comprising such compounds and to methods of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions. | 2012-11-08 |
20120283310 | MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CLL) and Uses Thereof - Methods and compositions for the diagnosis, prognosis and/or treatment of leukemia associated diseases are disclosed. | 2012-11-08 |
20120283311 | siRNA Targeting Glucagon Receptor (GCCR) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for GCGR. | 2012-11-08 |
20120283312 | MODULATION OF EIF4E EXPRESSION - Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided. | 2012-11-08 |
20120283313 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS - The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4. | 2012-11-08 |
20120283314 | SODIUM CHANNEL PROTEIN TYPE III ALPHA-SUBUNIT SPLICE VARIANT - The present invention is directed to a splice variant of a human sodium channel alpha subunit and methods and compositions for making and using the same. | 2012-11-08 |
20120283315 | SDF-1 DELIVERY FOR TREATING ISCHEMIC TISSUE - A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification. | 2012-11-08 |
20120283316 | Delivery of Therapeutic Agents Using Oligonucleotide-Modified Nanoparticles As Carriers - Disclosed are drug delivery compositions comprising an oligonucleotide-modified nanoparticle and a therapeutic agent. Specifically, disclosed are compositions comprising a number of oligonucleotide molecules in a ratio to therapeutic agent molecules to allow a sufficient transportation of the therapeutic agent molecules into a cell. The therapeutic agents include both hydrophobic and hydrophilic. Different attachments of therapeutic agents in a composition are also described. | 2012-11-08 |
20120283317 | Methods and Compositions for Regulating RNA Import into Mitochondria - Disclosed herein recombinant and/or isolated nucleic acid molecules which comprise, consist essentially of, or consist of a first nucleic acid sequence, which is a wild-type sequence or an altered sequence, directly or indirectly linked to a second nucleic acid sequence selected from the group consisting of: (1) a mitochondria localization sequence, (2) an RNA import sequence, or (3) a combination thereof, and methods of using thereof. | 2012-11-08 |
20120283318 | REPLICATING VIRAL VECTORS FOR GENE THERAPY - The present invention concerns the field of gene therapy and in particular the use of specific adenoviral vector systems for gene therapy, said vector systems offering enhanced efficiency and specificity for gene delivery. More specifically, the present invention provides replicating-competent adenoviral vector systems carrying one or more inserted heterologous gene. The adenoviral vectors system according to the invention are characterized by high binding efficiency and infectivity to cells of neural origin, endothelial cells, carcinoma cells and dendritic cells. | 2012-11-08 |
20120283319 | OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS - Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided. | 2012-11-08 |
20120283320 | STABLE, WATER-INSOLUBLE R-(+)-ALPHA-LIPOIC ACID SALT USEFUL FOR THE TREATMENT OF DIABETES MELLITUS AND ITS CO-MORBIDITIES - The present invention relates to oral nutritional and therapeutic products which are useful for preventing or treating compensated and decompensated insulin resistance and associated diseases and sequelae, or diabetes mellitus and its sequelae, complications, and co-morbidities, comprising magnesium R-(+)-alpha-lipoate. | 2012-11-08 |
20120283321 | USE OF GAMBIEROL FOR TREATING AND/OR PREVENTING NEURODEGENERATIVE DISEASES RELATED TO TAU AND BETA-AMYLOID - The present invention relates to the use of a compound with the following chemical structure: | 2012-11-08 |
20120283322 | Rhus Verniciflua Stokes Extract Having Increased Content Of Active Flavonoid Compound And Method For Preparing Same - The present invention relates to | 2012-11-08 |
20120283323 | Treating Learning Deficits with Inhibitors of HMG CoA Reductase - The disclosure provides methods of treating cognitive disorders by administering a HMG CoA reductase inhibitor. Cognitive deficits treatable with the inhibitor compound include those associated with Angelman Syndrome, Neurofibromatosis-1, certain forms of X-linked mental retardation, tuberous sclerosis, Down Syndrome, autism, and attention deficit/hyperactivity disorder. | 2012-11-08 |
20120283324 | ANTAGONISTS AND AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF - The present invention relates to antagonists and agonists of the human bitter-taste receptors hTAS2R40, hTAS2R43, hTAS2R44, hTAS2R46, and hTAS2R47. The invention also relates to methods for identifying further molecules that suppress or enhance bitter taste transduction or bitter taste response mediated by hTAS2R40, hTAS2R43, hTAS2R44, hTAS2R46, and/or hTAS2R47 and uses thereof. | 2012-11-08 |
20120283325 | EXCIPIENT COMPATIBILITY WITH EZATIOSTAT - Disclosed herein is the surprising and unexpected discovery that mannitol inhibits the growth of impurities and enhances shelf life of ezatiostat hydrochloride formulations. | 2012-11-08 |
20120283326 | ANTHRANILIC ACID DERIVATIVES - Compounds of formula (I) are provided, wherein X is CH═CH, CH | 2012-11-08 |
20120283327 | PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF A HYDROCORTISONE DERIVATIVE DESIGNATED AS DEINA - The hydrocortisone derivative of formula (I), whose IUPAC name is 3-[3,5-Dihydroxy-3-(2-hydroxy-acetyl)-3a,6-dimethyl-7-oxo-dodecahydro-cyclo-penta[alpha]naphthalen-6-yl]-propionic acid, designated as Deina®, is used in the treatment of atrophic tissues, particularly skin, cartilage, connective, and mucosal tissues and scalp skin. | 2012-11-08 |
20120283328 | PHOTOSENSITIZER COMPOSITION FOR TREATING SKIN DISORDERS - A composition comprising an active ingredient selected from the group of 5-aminolevulinic acid or a pharmaceutically acceptable salt or derivative thereof; and an aqueous carrier comprising at least one absorption enhancer, an anesthetic, hyaluronic acid and at least one acid selected from the group consisting of glycolic acid and lactic acid. The composition is useful in a photodynamic method of treating skin disorders. | 2012-11-08 |
20120283329 | S ISOMERS OF ALPHA-METHYL HYDROCINNAMIC ACID FOR THE TREATMENT OF BLOOD DISORDERS - The present intervention generally relates to compositions comprising S-isomer of alpha-methyl-hydrocinnamic acid for the treatment and/or prevention of blood disorders and blood deficiencies, as well as methods for treating blood disorders and/or blood deficiency in a subject by administering a composition comprising S-isomer of alpha-methyl-hydrocinnamic acid to the subject to ameliorate at least one symptom associated with the blood disorder. Another aspect relates to administration of an S-isomer of alpha-methyl-hydrocinnamic acid stimulate multi-lineage hematopoietic cell production in a subject, for example, increasing the numbers of circulating neutrophils, erythrocytes and platelets. Accordingly, one aspect of the present invention relates to administration of S-isomer of alpha-methyl-hydrocinnamic acid, e.g., by oral administration to a subject for the treatment of blood disorders, for example but not limited to, hemaglobinaphthy, thalassemia and aplastic anemia. In some embodiments, the oral pharmaceutical formulation comprising an S-isomer of -α-methyl-hydrocinnamic acid can be used to increase red blood cell proliferation, or increase the proliferation of hemoglobin-expressing cells in a subject in need thereof, e.g., a subject having a blood deficiency such as a subject undergone chemotherapy or radiation exposure or radiation therapy. In some embodiments, a formulation comprising an S-isomer of alpha-methyl-hydrocinnamic acid (ST7S) can be used to simulate myelopiesis or erythropoiesis in a subject in need thereof. | 2012-11-08 |
20120283330 | METHODS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - The present invention is directed to the use of a compound of formula (I) | 2012-11-08 |
20120283331 | Anti-Inflammatory Quinic Acid Derivatives for Radioprotection/Radiomitigation - Disclosed are methods of use of analogs of quinic acids or shikimic acids for protection from the harmful effects of radiation when administered either prior to radiation exposure, after radiation exposure, or both. These methods are useful for treating humans and animals exposed to radiation and at risk for radiation sickness and/or death as the result of radiation exposure. | 2012-11-08 |
20120283332 | TRANSDERMAL DELIVERY OF METFORMIN - Provided is a transdermal metformin that is an effective alternative treatment modality in patients with insulin resistance. Transdermal metformin can be used in conditions where oral metformin is indicated such as Type 2 diabetes mellitus, pre-diabetes, polycystic ovarian syndrome, and other known diabetes associated disorders. One advantage of using transdermal metformin is its ability to bypass the gastrointestinal system. This allows the drug to not have the gastrointestinal side-effects associated with oral metformin. A surprising advantage of using transdermal metformin in accordance with this disclosure is a 90% decrease in dosage from the oral preparation. | 2012-11-08 |
20120283333 | Ophthalmic Compositions with an Amphoteric Surfactant, Hyaluronic Acid and Polyquaternium-1 - Ophthalmic compositions that comprise 0.5 ppm to 15 ppm α-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-Ω-tris(2-hydroxyethyl) ammonium chloride; 0.005 wt. % to 0.05 wt. % hyaluronic acid; citrate, citric acid or a mixture thereof; and 0.01 wt. % to 0.8 wt. % of an amphoteric surfactant of general formula I | 2012-11-08 |
20120283334 | Treatment of Viral Infections - The invention provides compositions, medicaments and methods of treatment of viral infections, especially respiratory disorders caused by viral infections. In particular, the invention relates to the treatment of acute viral infections using a range of related 1-phenyl-2-amino ethanol, ethanal, and ethane derivatives. | 2012-11-08 |
20120283335 | Analogs of Propofol, Preparation Thereof and Use as Anesthetics - Compounds of formula (I) wherein X is H or F and pharmaceutically acceptable salts thereof are useful as anesthetics. | 2012-11-08 |
20120283336 | PREPARATION OF SHAPED METAL PARTICLES AND THEIR USES - The instant invention relates to shaped transition metal particles, in particular in the form of a dispersion in an aqueous and/or organic medium, the manufacture thereof and their use as an infrared (IR) absorbing agent, an IR curing agent for coatings, an additive in conductive formulations, an antimicrobial agent or for sensoring organic and/or inorganic compounds. Further, the invention relates to dispersions comprising said shaped particles and an aqueous and/or organic medium, such as a thermoplastic or crosslinkable polymer, as well as to antimicrobial compositions and products. | 2012-11-08 |
20120283337 | INORGANIC POROUS PARTICLES WITH STABILIZED MICROPORES - Sol-gel inorganic porous particles can be formed with two set of pores with different average sizes. These inorganic porous particles are composed of an inorganic compound that provides an inorganic solid phase including an external particle surface. They also have a first set of pores wherein the pores have an average diameter of less than 100 nm and a second set of pores wherein the pores have an average diameter of at least 100 nm. The second set of pores contains stabilizing organic microgel particles. The first and second sets of pores are isolated from each other within the inorganic solid phase. | 2012-11-08 |
20120283338 | SWEETENER COMPOSITIONS AND METHODS OF MAKING THE SAME - Disclosed is a method of preparing a composition by mixing a sweetener and an ingredient, pressing the sweetener and ingredient together to form a pressed mixture in the form of a sheet, briquette, pellet, flake or other form, and reducing the pressed mixture to yield a composition. The composition comprises particulates having a desirable size, where a particulate comprises the ingredient at least partially embedded within the sweetener. The composition can be used in a variety of food, dietary and pharmaceutical products. | 2012-11-08 |
20120283339 | HFO-1234ZE MIXED ISOMERS WITH HFC-245FA AS A BLOWING AGENT, AEROSOL, AND SOLVENT - A composition which is a blowing agent which comprises from about 75% to about 90% by weight trans-1,3,3,3-tetrafluoropropene, from about 1% to about 15% by weight cis-1,3,3,3-tetrafluoropropene, and from about 1% about 15% by weight 1,1,3,3,3-pentafluoropropane. | 2012-11-08 |
20120283340 | PROCESS FOR PRODUCING METHANOL - The present invention relates to a novel process for the production of methanol. The process comprises the heterolytic cleavage of hydrogen by a frustrated Lewis pair comprising a Lewis acid and a Lewis base; and the hydrogenation of CO | 2012-11-08 |
20120283341 | System and Method for Converting Biomass to Ethanol via Syngas - A method and apparatus for synthesizing ethanol using synthetic routes via synthesis gas are disclosed. A method and apparatus for gasifying biomass, such as biomass, in a steam gasifier that employs a fluidized bed and heating using hot flue gases from the combustion of synthesis gas is described. Methods and apparatus for converting synthesis gas into ethanol are also disclosed, using stepwise catalytic reactions to convert the carbon monoxide and hydrogen into ethanol using catalysts including iridium acetate. | 2012-11-08 |
20120283342 | CATALYSTS FOR THE CONVERSION OF SYNTHESIS GAS TO ALCOHOLS - The present application includes alkali metal-promoted trimetallic catalysts for higher alcohol synthesis from synthesis gas, the catalyst comprising a catalyst of Formula (1): | 2012-11-08 |
20120283343 | ION EXCHANGE REGENERATION AND UPW TREATMENT SYSTEM - An improved process for regenerating ion exchange resin, includes a regeneration step of displacing captured ions from the resin to regenerate its ion-capture functionality, followed by one or more fluid-employing post-regeneration steps such as a fluid displacement or rinse, a fluid transporting or mixing, and a rinse down to quality. To avoid problems of early leakage of weakly held ions such as boron, the post-chemical or postdisplacement steps use water that is essentially free of boron, or otherwise avoid localized contamination in the regenerated resin which is used in bottles or beds ( | 2012-11-08 |
20120283344 | EXPANDED PARTICLE OF POLYETHYLENE-BASED RESIN AND IN-MOLD EXPANSION MOLDED ARTICLE OF POLYETHYLENE-BASED RESIN - A polyethylene resin expanded particle has an expansion ratio of not less than 10 times and not more than 50 times, and in a DSC curve obtained by differential scanning calorimetry (DSC), the polyethylene resin expanded particle (i) shows two melting peaks, the two melting peaks being a low-temperature side melting peak and a high-temperature side melting peak, and (ii) further has a shoulder in a region not less than 100° C. and not more than the low-temperature side melting peak temperature, the shoulder having a shoulder ratio which is not less than 0.2% and not more than 3%. This makes it possible to obtain a polyethylene resin expanded particle for producing a polyethylene resin in-mold expansion molded article in which especially an end (edge part) of the polyethylene resin in-mold expansion molded article is excellent in fusion bond level and appearance and which has neither a wrinkle nor a void on a surface thereof, is excellent in surface property (has a beautiful surface), and has a high expansion ratio. | 2012-11-08 |
20120283345 | HEAT-RESISTANT AND FLAME-RETARDANT EXTRUDED FOAM MADE OF STYRENE COPOLYMERS - The invention is directed to extruded foam based on thermoplastic polymers. The foam contains at least one styrene copolymer which contains copolymerized maleic anhydride units or copolymerized maleimide units, and optionally styrene-acrylonitrile copolymers (SAN), and thermoplastic polymers and at least one halogen-containing polymer as flame retardant, and at least one flame retardant synergist selected from antimony trioxide and dicumyl. The invention also relates to a process for producing the foam with introducing carbon dioxide as blowing agent, and acetone as coblowing agent; into the polymer melt in order to form a foamable melt, and extruding the foamable melt into a region of relatively low pressure with foaming to give the extruded foam. The invention also relates to the use of said foam as insulation material and as structural foam. | 2012-11-08 |
20120283346 | Modified Polyolefins - The invention provides a process for grafting silane or silicone functionality onto a polyolefin, comprising reacting the polyolefin with an unsaturated monomer (A) containing an olefinic —C═C— bond or acetylenic —C≡C— bond and a reactive functional group X in the presence of means capable of generating free radical sites in the polyolefin and with an organosilicon compound (B) having a functional group Y which is reactive with the functional group X of the unsaturated monomer (A), characterized in that the unsaturated monomer (A) contains an aromatic ring or a further olefinic double bond or acetylenic unsaturation, the aromatic ring or the further olefinic double bond or acetylenic unsaturation being conjugated with the olefinic —C═C— or acetylenic —C≡C— unsaturation of the unsaturated monomer (A). | 2012-11-08 |
20120283347 | EXPANDED PARTICLE OF NONCROSSLINKED POLYETHYLENE-BASED RESIN AND EXPANSION MOLDED ARTICLE OF NONCROSSLINKED POLYETHYLENE-BASED RESIN - A noncrosslinked polyethylene resin expanded particle is provided having a bulk density in a range of 10 g/L to 100 g/L, the particle being obtained by expanding a polyethylene resin particle whose density is in a range of 0.920 g/cm | 2012-11-08 |
20120283348 | METHOD AND DEVICE FOR CURING A THERMOSETTING POLYMER - The present invention concerns a method and a device for curing a thermosetting polymer. The method comprises the steps of irradiating the thermosetting polymer with microwaves at a first power level so as to heat up the thermosetting polymer by dielectric heating, and when the thermosetting polymer reaches a first predetermined temperature, irradiating the thermosetting polymer with microwaves at a second power level, substantially higher than the first power level, to further heat up the thermosetting polymer by dielectric heating. The device comprises an enclosure for receiving the thermosetting polymer, a microwave emitter for emitting microwave radiation into the enclosure, and a control unit for controlling a microwave emission power of the microwave emitter according to the abovementioned method. | 2012-11-08 |
20120283349 | UV-LED CURABLE COMPOSITIONS AND INKS - A radiation curable composition for UV LED curing includes at least one co-initiator selected from the group consisting of an aliphatic tertiary amine and a dialkyl aniline derivative; and at least one specific carbazole photoinitiator. The radiation curable composition can be advantageously used to prevent unstable yellowing behaviour in an image upon storage. | 2012-11-08 |
20120283350 | RESIN COMPOSITION FOR COATING MATERIAL - The invention aims to provide a resin composition having favorable stain resistance and storage stability even in the form of a one-pack coating material. Provided is a resin composition for a coating material, including: (I) a synthetic resin emulsion; (II) a silicon compound represented by the formula (1): | 2012-11-08 |
20120283351 | NITRILE RUBBERS AND PRODUCTION THEREOF IN ORGANIC SOLVENTS - A new process is provided for preparing nitrile rubbers by free-radical polymerization in an organic solvent and in the presence of specific modifier substances. This polymerization may be followed by hydrogenation to give likewise new hydrogenated nitrile rubbers, the hydrogenation advantageously taking place likewise in organic solvent. The optionally hydrogenated nitrile rubbers obtained are notable for having fragments of the employed modifier substances in the main polymer chain and/or as end groups. They can he prepared with a wide diversity of molecular weights and polydispersity indices, especially with very low polydispersity indices. | 2012-11-08 |
20120283352 | CHAIN CURING RESIN COMPOSITION AND FIBER-REINFORCED COMPOSITE MATERIAL - Provided is an RTM moldable chain curing resin composition which can be molded with less energy in a short time, and which makes it possible to obtain a cured product that is superior in mechanical strength. A chain curing resin composition of the present invention includes an alicyclic epoxy compound (A) having two cyclohexene oxides in a molecule and a specific modified bisphenol A-type epoxy resin (B), and the content of the alicyclic epoxy compound (A) is 25 to 90% by mass, when the total of the component (A) and the component (B) is taken as 100% by mass. | 2012-11-08 |
20120283353 | MEDICAL DEVICES HAVING HOMOGENEOUS CHARGE DENSITY AND METHODS FOR MAKING SAME - The present invention relates to ionic silicone hydrogel polymers displaying improved lysozyme uptake, low contact angle and reduced water soluble polymeric ammonium salt uptake. | 2012-11-08 |
20120283354 | TYRE RUBBER COMPOSITION AND PNEUMATIC TYRE - The present invention provides a tire rubber composition which has good silica dispersibility and improves in terms of the reinforcement, the abrasion resistance, the mechanical strength, the rolling resistance, the wet grip performance, and the handling stability on a dry road surface in a balanced manner; and provides a pneumatic tire produced using the tire rubber composition. The present invention relates to a tire rubber composition, comprising: a rubber component; a first silica; and a second silica, wherein the first silica has a CTAB specific surface area of 180 m | 2012-11-08 |
20120283355 | Tire Composition Using Elastomer Composite Blends - A tire comprising a rubber composition based on at least an elastomer composite prepared by a method comprising: feeding a continuous flow of a first fluid comprising a first elastomer latex to a mixing zone of a coagulum reactor; feeding a continuous flow of a second fluid comprising a second elastomer latex to the mixing zone; feeding a continuous flow of a third fluid comprising a particulate filler slurry to the mixing zone; allowing the first elastomer latex and the second elastomer latex to coagulate with the particulate filler; and discharging a flow of elastomer composite from a discharge end of the coagulum reactor. | 2012-11-08 |
20120283356 | THERMOSETTABLE RESIN COMPOSITIONS - A reactive thermosettable resin composition including (a) at least one thermosetting resin; (b) at least one curing agent, and (c) optionally, at least one catalyst; wherein the curing agent (b) comprises a reactive inorganic cluster; and wherein the clusters are storage-stable inorganic clusters with reactive functional groups, such as amino groups; a process for preparing a thermoset product from the thermosettable composition. A composition of the reactive clusters as a curing agent and a thermosetting resin may be used to prepare thermoset products with improved thermo-mechanical behavior. | 2012-11-08 |
20120283357 | CURABLE PHOSPHORUS-CONTAINING FLAME RETARDANT EPOXY RESIN - This invention relates to an epoxy resin composition, in particular a curable phosphorus containing flame retardant epoxy resin composition comprising epoxy resin and an epoxy resin chain-extending amount of a diaryl alkylphosphonate and/or diaryl arylphosphonate and a cross-linking agent. The curable flame retardant compositions are useful in e.g., printed wiring boards or molding compounds for electronic applications, protective coatings, adhesives, as well as structural and decorative composite materials. | 2012-11-08 |
20120283358 | ADHESIVE COMPOSITION FOR USE IN AN IMMUNOSENSOR - An adhesive composition for use in devices and methods for measuring a presence or a concentration of a particular component, such as an antigen, in a sample, such as blood, are provided. In one exemplary embodiment of an adhesive composition, the composition includes an adhesive, water, a poloxamer, and an anticoagulant. The adhesive can include particular properties, such as being hydrophilic, pressure-sensitive, heat-activated, and/or water soluble. The adhesive is particularly useful because it can help improve the flow of sample a device. For example, when the device is an immunosensor, the adhesive can help prevent the blood from clotting in chambers of the immunosensor. This results in a more efficient and accurate determination of the concentration of the sample. Methods of making the composition and device in which the composition can be used are provided, as are methods of using the same. | 2012-11-08 |
20120283359 | BISPHENOL-A REPLACEMENT MATERIALS - Polymers may include a plurality of tetradecahydroanthracene moieties. Such polymers may be used to make food or beverage containers or medical devices. Food or beverage containers or medical devices may be coated with polymers including a plurality of tetradecahydroanthracene moieties. | 2012-11-08 |
20120283360 | Rubber Composition Including an Expoxide Resin - A rubber composition which can be used in particular in tires, based on at least one diene elastomer, one reinforcing filler, one crosslinking system, between 1 and 20 phr of an epoxide resin and between 1 and 15 phr of an amine-comprising curing agent. The pair formed of epoxide resin with an amine-comprising curing agent advantageously replaces the pair formed of phenol/formaldehyde resin, which is a methylene acceptor, with the curing agent(s) HMT or H3M, which are conventional methylene donors. The use of this pair of reactants, epoxide resin and amine-comprising curing agent, makes it possible to obtain rubber compositions exhibiting a greater low-strain stiffness in comparison with conventional rubber compositions, without significantly damaging the hysteresis. Moreover, the combination of a phenolic resin, which is a methylene acceptor, with HMT or H3M, which is a methylene donor, produces formaldehyde during the vulcanization of the rubber composition. In point of fact, it is desirable to reduce, indeed even in the long run to eliminate, the formaldehyde of rubber compositions due to the environmental impact of this compound. | 2012-11-08 |
20120283361 | BULK MATERIAL COVER COMPOSITIONS AND METHODS OF APPLYING - A cover material for a bulk material pile and method for applying the cover material are disclosed. The cover composition comprises liquid, cement and/or fly ash, fiber, water dispersible polymer and acid. | 2012-11-08 |
20120283362 | ORGANOPOLYSILOXANES CONTAINING AN UNSATURATED GROUP - The invention provides a composition comprising a polyolefin and a polyorganosiloxane in which at least 50 mole % of the siloxane units are D units as herein defined and which contains at least one unsaturated group, characterized in that the unsaturated group is group of the formula —X—CH═CH—R″ (I) or —X—C≡C—R″ (II), in which X represents a divalent organic linkage having an electron withdrawing effect with respect to the —CH═CH— or —C≡C— bond and/or containing an aromatic ring or a further olefinic double bond or acetylenic unsaturation, the aromatic ring or the further olefinic double bond or acetylenic unsaturation being conjugated with the olefinic unsaturation of —X—CH═CH—R″ or with the acetylenic unsaturation of —X—C≡C—R″ and R″ represents hydrogen or a group having an electron withdrawing effect or any other activation effect with respect to the —CH═CH— or —C≡C— bond. | 2012-11-08 |
20120283363 | COMPOSITE MATERIAL - A composite material of the invention is a mixture of cellulose microfibers having a carboxyl group content of 0.1 to 3 mmol/g and a moldable polymeric material selected from the group consisting of a biomass-derived polymer and a petroleum-derived polymer. The biomass-derived polymer is preferably polylactic acid or pulp. The cellulose microfibers are preferably present in an amount of 0.01% to 60% by mass. Another composite material of the invention is a mixture of cellulose composite microfibers and a moldable resin, the cellulose composite microfibers being obtained by adsorbing a surfactant onto cellulose microfibers having a carboxyl group content of 0.1 to 3 mmol/g. | 2012-11-08 |
20120283364 | POLYMER BLENDS COMPRISING PHASE-ENCAPSULATED THERMOPLASTIC STARCH AND PROCESS FOR MAKING THE SAME - New polymer blends are provided. These blends comprise a first polymer, a second polymer and thermoplastic starch, the thermoplastic starch being at least partially encapsulated in the second polymer. The polymer blends may be shaped into articles, for example by extrusion or injection molding. | 2012-11-08 |
20120283365 | STOCK SOLUTIONS HAVING HIGH CONCENTRATIONS OF POLYMERS BASED ON OILS OF PLANT AND/OR ANIMAL ORIGIN FOR THE PREPARATION OF BITUMEN/POLYMER COMPOSITIONS - The present disclosure relates to a mother solution free from oil of petroleum origin including at least one oil of vegetable and/or animal origin, from 20% to 50% by mass of polymer, with respect to the mass of the mother solution, with or without at least one cross-linking agent, the oil of vegetable and/or animal origin being acid, with an acid value measured according to the standard NF EN ISO 660 including between 50 and 300 mg KOH/g. This mother solution with a very high concentration of polymer is stable and does not gel and can therefore be diluted and used for preparing cross-linked bitumen/polymer compositions, then bituminous mixes. | 2012-11-08 |
20120283366 | ACTIVATED OXYGEN SCAVENGING COMPOSITIONS FOR PLASTIC CONTAINERS - The present invention provides a composition comprising: a polyester base polymer; at least one non-polymeric oxidizable organic compound; at least one transition metal in a positive oxidation state, said metal being present in the composition in an amount of from about 10 to about 400 ppm; and at least one activator compound selected from the group consisting of: (i) a polyester ionomer containing a sulfoisophthalate moiety, (ii) a polyol derivative and (iii) a N-hydroxyimide, wherein the at least one non-polymeric oxidizable organic compound is present in an amount of from about 0.10 to about 10 weight percent of the composition, and wherein the at least one activator compound is present in an amount of from about 0.01 to about 5 weight percent of the composition. The compositions of the present invention do not exhibit an induction period prior to the onset of oxygen scavenging upon formation into a container. | 2012-11-08 |
20120283367 | ANTISTATIC THERMOPLASTIC COMPOSITIONS - The instant invention pertains to the use of an antistatic composition comprising a polar thermoplastic polymer and an ionic liquid as antistatic additive for non-polar thermo-plastic or elastomeric polymers. Further aspects of the invention are a process for the preparation of an antistatic non-polar thermoplastic or elastomeric polymer which process comprises incorporating therein a mixture of a polar thermoplastic polymer and an ionic liquid and the composition of a polar thermoplastic polymer, an ionic liquid and a non-polar thermoplastic or elastomeric polymer. | 2012-11-08 |
20120283368 | SURFACE TREATED CALCIUM CARBONATE FILLER FOR RESIN AND RESIN COMPOSITION CONTAINING THE FILLER - Provided is a surface treated calcium carbonate filler for resins, which comprises calcium carbonate particles, the surface of which has been treated with at least one surface active agent (A) selected from the group consisting of saturated fatty acids, unsaturated fatty acids, alicyclic carboxylic acids, resin acids, and salts thereof and with at least one compound (B) having the ability to chelate alkaline earth metals, the compound (B) being selected from the group consisting of phosphonic acids, polycarboxylic acids, and salts thereof. The surface treated calcium carbonate filler for resins of the present invention deteriorates little with time, has satisfactory dispersibility in resins, and can give a sheet or film which has a satisfactory balance among durability, weatherability, strength, and thermal stability, and is useful as a battery separator or a light reflector. | 2012-11-08 |